You are here

  • Home
  • Online First
  • Generalised urticaria and angioedema complicating switch back from subcutaneous to intravenous vedolizumab therapy

Article Text

Article menu
Download PDFPDF
Colorectal
Case report
Generalised urticaria and angioedema complicating switch back from subcutaneous to intravenous vedolizumab therapy
  1. Dipesh Chauhan1,
  2. Anil Prabhu2,
  3. Sarah Cripps1,
  4. Siraj Misbah3,
  5. Kate Griffiths2,
  6. Alice Roseman2,
  7. Alissa Walsh2,
  8. Jack Satsangi2
  1. 1Pharmacy Department, John Radcliffe Hospital, Oxford, UK
  2. 2Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK
  3. 3Department of Clinical Immunology, John Radcliffe Hospital, Oxford, UK
  1. Correspondence to Dr Anil Prabhu, Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK; anil_prabhu{at}hotmail.co.uk

Abstract

We report a unique case of a 34-year-old man with ulcerative colitis, previously in complete remission with intravenous vedolizumab monotherapy, who developed an urticarial injection-site reaction on switching to a subcutaneous preparation and thereafter experienced a new hypersensitivity reaction on switch back to intravenous vedolizumab, necessitating complete discontinuation from this drug. This case highlights the need for vigilance on switching back to intravenous preparations of vedolizumab, in response to injection-site reactions with a subcutaneous preparation, even if the intravenous preparation had been previously well tolerated by the patient.

  • ULCERATIVE COLITIS
  • ADVERSE DRUG REACTIONS

http://dx.doi.org/10.1136/flgastro-2023-102380

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors No additional writing assistance was used for this paper. DC and AP: drafting and revising the article for important intellectual content and final approval. SC, JS and SM: revising the article for important intellectual content and final approval. AW and KG: final approval.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests DC has no conflicts of interest to declare. AP has no conflicts of interest to declare. SC has received consulting fees from AbbVie, Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen Pharmaceuticals, Sandoz, Takeda and Warner Chilcott. AW has received research grants or consulting fees from AbbVie, Bühlmann Laboratories, Galapagos, GSK, Janssen Pharmaceuticals, Lilly, Pfizer, Takeda and Vifor Pharma. SM has no conflicts of interest to declare. KG has no conflicts of interest to declare. JS is a member of the steering committee of the PYRAMID phase IV study of safety of adalimumab in Crohn’s disease and coinvestigator in the Verdict phase IV study of vedolizumab in ulcerative colitis.

    • Provenance and peer review Not commissioned; externally peer reviewed.